Search
Loading Complete
Raphael P. Viscidi

Raphael P. Viscidi, MD

Highlights

Languages

  • English

Gender

Male

Johns Hopkins Affiliations:

  • Johns Hopkins School of Medicine Faculty

About Raphael P. Viscidi

Primary Academic Title

Professor of Pediatrics

Background

Dr. Raphael P. Viscidi is a professor of pediatrics and oncology at the Johns Hopkins University School of Medicine. He is also on faculty at the Johns Hopkins Bloomberg School of Public Health. 

As a virologist, Dr. Viscidi focuses much of his research on human papillomavirus and polyomaviruses. He also is interested in the seroepidemiology of human coronaviruses, population genetics of Neisseria gonorrhoeae, development of an avian influenza virus-like particle vaccine and development of a SARS-coronavirus vaccine.

Dr. Viscidi received his medical degree from SUNY Downstate Medical Center College of Medicine.

 

Centers and Institutes

Additional Academic Titles

Professor of Oncology

Contact for Research Inquiries

Phone: (410) 614-1494
rviscid1@jhmi.edu

Research Interests

Development of avian influenza virus like particle (VLP) vaccine, Development of SARS-coronavirus vaccine, Pathogenesis and seroepidemiology of human papillomavirus, Pathogenesis and seroepidemiology of human polyomaviruses, Population genetics of Neisseria gonorrhoeae, Seroepidemiology of human coronaviruses

Research Summary

Dr. Viscidi conducts research related to human papillomavirus (HPV) and polyomaviruses (PV). Both viruses encode oncoproteins and thus are the subject of continuing investigations as causative agents in diverse human cancers.

For the last several years, Dr. Viscidi’s laboratory has studied humoral immune responses to HPV and PV using virus-like particles (VLP) based enzyme linked immunosorbent assays. He has conducted many cancer case control and population-based seroepidemiological studies of HPV and PV infection. His laboratory has expertise in production of virus-like particles using the baculovirus expression system, and they are working to develop VLP-based vaccines and studies of immunological properties of VLPs.

The laboratory also explores applications of a novel chimeric VLP construct, invented by Dr. Viscidi, as a platform for vaccines against cancer and infectious agents, including malaria and human immunodeficiency virus. He also studies how VLP-based vaccines activate innate immune responses and is conducting studies of global gene expression in subpopulations of peripheral blood immune cells in response to VLP vaccination. Another very different area of study in the laboratory is population genetics of Neisseria gonorrhoeae and the molecular evolution of antibiotic resistance.

Selected Publications

  • Beachler DC, Viscidi R, Sugar EA, Minkoff H, Strickler HD, Cranston RD, Wiley DJ, Jacobson LP, Weber KM, Margolick JB, Reddy S, Gillison ML, D'Souza G. “A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection.” Sex Transm Dis. 2015 Feb;42(2):93-7. doi: 10.1097/OLQ.0000000000000236.

  • Hampras SS, Viscidi RP, Helzlsouer KJ, Lee JH, Fulp WJ, Giuliano AR, Platz EA, Rollison DE. “Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas.” Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2591-6. doi: 10.1158/1055-9965.EPI-14-0370. Epub 2014 Aug 15.

  • Koshiol, J.; Wei, W.Q.; Kreimer, A.R.; Chen, W.; Gravitt, P.; Ren, J.S.; Abnet, C.C.; Wang, J.B.; Kamangar, F.; Lin, D.M.; von Knebel-Doeberitz, M.; Zhang, Y.; Viscidi, R.; Wang, G.Q.; Gillison, M.L.; Roth, M.J.; Dong, Z.W.; Kim, E.; Taylor, P.R.; Qiao, Y.L.; Dawsey, S.M. No role for human papillomavirus in esophageal squamous cell carcinoma in China. Int J Cancer. 2010 Jul 1;127(1):93-100.

  • Pejawar-Gaddy, S.; Rajawat, Y.; Hilioti, Z.; Xue, J.; Gaddy, D.F.; Finn, O.J.; Viscidi, R.P.; Bossis, I. Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol Immunother. 2010 Nov;59(11):1685-1696.

  • Randhawa, P.; Viscidi, R.; Carter, J.J.; Galloway, D.A.; Culp, T.D.; Huang, C.; Ramaswami, B.; Christensen, N.D. Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies. J Gen Virol. 2009 Mar;90(Pt 3):634-639.

  • Rollison, D.E.; Helzlsouer, K.J.; Lee, J.H.; Fulp, W.; Clipp, S.; Hoffman-Bolton, J.A.; Giuliano, A.R.; Platz, E.A.; Viscidi, R.P. Prospective study of JC virus seroreactivity and the development of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1515-1523.

  • Rossi F, Newsome SD, Viscidi R. “Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.” Mol Cell Probes. 2015 Feb;29(1):54-62. doi: 10.1016/j.mcp.2014.11.007. Epub 2014 Dec 5.

  • Silver MI, Rositch AF, Burke AE, Chang K, Viscidi R, Gravitt PE. “Patient concerns about human papillomavirus testing and 5-year intervals in routine cervical cancer screening.” Obstet Gynecol. 2015 Feb;125(2):317-29. doi: 10.1097/AOG.0000000000000638.

  • Soares CC, Georg I, Lampe E, Lewis L, Morgado MG, Nicol AF, Pinho AA, Salles RC, Teixeira SL, Vicente AC, Viscidi RP, Gomes SA. “HIV-1, HBV, HCV, HTLV, HPV-16/18, and Treponema pallidum infections in a sample of Brazilian men who have sex with men.” PLoS One. 2014 Aug 1;9(8):e102676. doi: 10.1371/journal.pone.0102676. eCollection 2014.

  • Sutcliffe, S.; Kawachi, I.; Alderete, J.F.; Gaydos, C.A.; Jacobson, L.P.; Jenkins, F.J.; Viscidi, R.P.; Zenilman, J.M.; Platz, E.A. Correlates of sexually transmitted infection histories in a cohort of American male health professionals. Cancer Causes Control. 2009 Nov;20(9):1623-1634.

  • Sutcliffe, S.; Viscidi, R.P.; Till, C.; Goodman, P.J.; Hoque, A.M.; Hsing, A.W.; Thompson, I.M.; Zenilman, J.M.; De Marzo, A.M.; Platz, E.A. Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):614-618.

  • Tan, C.S.; Chen, Y.; Viscidi, R.P.; Kinkel, R.P.; Stein, M.C.; Koralnik, I.J. Discrepant findings in immune responses to JC virus in patients receiving natalizumab. Lancet Neurol. 2010 Jun;9(6):565-566; author reply 566-567.

  • Trimble, C.L.; Peng, S.; Kos, F.; Gravitt, P.; Viscidi, R.; Sugar, E.; Pardoll, D.; Wu, T.C. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009 Jan 1;15(1):361-367.

  • Viscidi, R.P.; Shah, K.V. Adult male circumcision: will it reduce disease caused by human papillomavirus? J Infect Dis. 2010 May 15;201(10):1447-1449.

  • Wuthrich, C.; Dang, X.; Westmoreland, S.; McKay, J.; Maheshwari, A.; Anderson, M.P.; Ropper, A.H.; Viscidi, R.P.; Koralnik, I.J. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol. 2009 Jun;65(6):742-748.

Graduate Program Affiliations

  • Bloomberg School of Public Health

Additional Training

Education
M.D.
SUNY Downstate Medical Center College of Medicine
1975
Brooklyn, NY